UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):December 8, 2015
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-35737 | 94-3306718 |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |
4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 |
(Address of principal executive offices) |
(204) 497-9024 |
(Registrant’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
Item 8.01 Other Events
On December 8, 2015, Northwest Biotherapeutics, Inc, (the "Registrant") issued a press release regarding the establishment of a special committee for an independent investigation of recent allegations in an anonymous internet report and similar allegations contained in a derivative lawsuit (i.e., Yonemura case filed in Maryland on November 19, 2015).
Also on December 8, 2015, the Registrant issued a press release regarding certain Company appointments.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
99.1 | Press Release dated December 8, 2015 | |
99.2 | Press Release dated December 8, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NORTHWEST BIOTHERAPEUTICS, INC. | |||
Date: December 14, 2015 | By: | /s/ Linda Powers | |
Name: Linda Powers | |||
Title: Chief Executive Officer |